Our Story
Recordati established rare diseases operations in the Nordic and Baltic regions in 2007 as part of Recordati Rare Diseases. In 2018 the Recordati Speciality and Primary Care business unit was incorporated together with the Rare Disease business unit in Recordati AB. Today Recordati AB operates across the Nordic and Baltic regions from our regional office in Stockholm, Sweden.
Our Story
Recordati was established in the Nordic and Baltic regions with the rare diseases portfolio in 2007 due to the acquisition of Orphan Europe. In 2018 the Recordati Speciality and Primary Care business unit was incorporated together with the Rare Disease business unit in Recordati AB. Today Recordati AB operates across the Nordic and Baltic regions from our regional office in Stockholm, Sweden.
Recordati will bring treatment options across specialty and primary care and rare diseases business units, and has operations worldwide, including here in the Nordics-Baltics with a well-diversified portfolio of prescription drugs, available to healthcare professionals and patients, and offered in most Nordics-Baltics markets.
Our purpose and corporate philosophy is to give people the opportunity to unlock the full potential of life and to bring a brighter future to patients across the world.
We believe that health, and the opportunity to live life to the fullest, is a right, not a privilege.
Specialty and Primary care Nordics focuses mainly on the following therapeutical areas: cardiovascular, central nervous system, gastrointestinal, urological.
Recordati is a global international pharmaceutical company, Headquartered in Milan, Italy and listed on the Italian stock exchange. With over 4,450 employees, we develop and commercialise medicines to serve people living with common diseases, as well as those living with some of the rarest, in around 150 countries.
The Nordics-Baltics headquarter operates from Stockholm and consists of 24 employees within commercial, medical, finance, supply chain, regulatory and QA.
Focused on the few.
The Rare Diseases business unit is focused on providing the most effective treatment for unmet medical needs, mainly of genetic origin and caused by metabolic disorders, endocrine diseases, rare oncology pathologies.
Underpinned by a history of strong financial delivery, we will continue to grow from within, capture opportunities within our own pipeline, and identify opportunities to bring in new treatments through partnerships & acquisitions across all our businesses.
MILESTONES
1926
Giovanni Recordati founds the Laboratorio Farmacologico Reggiano in Correggio (RE, Italy)
1953
Transfer of headquarters to Milan
1961
Recordati – Syntex (now part of Roche) licence agreement. Located in Silicon Valley, Syntex was a pioneering company in the study and synthesis of steroid hormones
1963
Inauguration of the pharmaceutical chemical plant in Campoverde di Aprilia
1984
Listing on the Italian Stock Exchange
1995
Beginning the process of internationalisation – Establishment of a subsidiary in Spain, now called Casen Recordati
1999
Acquisition of Doms Adrian (France)
2000
Acquisition of Bouchara (France)
2001
Establishment of Bouchara Recordati in France
2005
- Acquisition of Merckle Recordati in Germany, now Recordati Pharma
- Establishment of Recordati Pharmaceuticals in the United Kingdom
- Establishment of Recordati Hellas in Greece
- Establishment of the new pharmaceutical chemical plant in Cork, Ireland
2006
Acquisition of the Grupo Jaba companies in Portugal, today Jaba Recordati
2007
Entry to the rare diseases sector with the acquisition of Orphan Europe, now Recordati Rare Diseases
2008
- Acquisition of FIC and FIC Médical, dedicated to the registration and promotion of pharmaceutical products in Russia and other Commonwealth of Independent States (C.I.S.) countries
- Acquisition of Yeni Ilaç in Turkey, today Recordati Ilaç
2009
Acquisition of Herbacos-Bofarma in the Czech Republic and Slovakia, today Herbacos Recordati
2010
Acquisition of ArtMed International in Romania, now Recordati Romania
2011
Acquisition of Dr. F. Frik Ilaç in Turkey, now Recordati Ilaç
2012
- Entry into the US market rare diseases sector
- Acquisition of product portfolio for the treatment of a number of rare diseases in the US
- Acquisition of Farma-Projekt in Poland, now Recordati Polska
2013
- Acquisition of Opalia Pharma and its cGMP certified production facilities in Tunisia, now Opalia Recordati
- Acquisition of Laboratorios Casen Fleet and its cGMP certified production facilities in Spain, now Casen Recordati
2015
Establishment of new subsidiaries in Brazil, Mexico and Colombia
2016
- SPC and OTC portfolio strengthened
- Acquisition of Italchimici in Italy
- Acquisition of Pro Farma AG, now Recordati AG, in Switzerland and Austria
2017
- Acquisition of Natural Point in Italy
- Acquisition of Tonipharm in France
- Establishment of new subsidiaries in Japan and Australia
2019
- Expansion of the rare diseases product portfolio: entry into the endocrinology sector
- Establishment of Recordati Bulgaria
2022
- Acquisition of EUSA Pharma (UK) Ltd, a global specialist pharmaceutical company focused on rare diseases and niche oncology
2023
-
Recordati announces an agreement with GSK to commercialize Avodart® (dutasteride) and Combodart®/Duodart®